Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
Clinical trial NCT05862337 · RECRUITING
Trial details
- NCT number
- NCT05862337
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-10
- Primary completion
- 2024-08-01
- Enrollment
- 480
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.